Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.
about
Mitoxantrone induces natural killer cell maturation in patients with secondary progressive multiple sclerosisAxonal transport rate decreased at the onset of optic neuritis in EAE miceTherapy-related acute promyelocytic leukemia: a systematic review.Presenting features and treatment outcome of acute promyelocytic leukemia arising after multiple sclerosis.Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) studyLights and shadows of cyclophosphamide in the treatment of multiple sclerosisGlobal characteristics of childhood acute promyelocytic leukemia.Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in GermanyAcute myeloid leukemia developing in patients with autoimmune diseases.Clinical and pathologic features of secondary acute promyelocytic leukemia.Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.Diagnosis and treatment of multiple sclerosis in pediatric and adolescent patients: current status and future therapies.The evolving challenge of therapy-related myeloid neoplasms.Treatment of multiple sclerosis in children and adolescents.Therapies for multiple sclerosis: considerations in the pediatric patient.Principles of a new treatment algorithm in multiple sclerosis.Multiple sclerosis therapeutic pipeline: opportunities and challenges.Management of children with multiple sclerosis.The management of pediatric multiple sclerosis.Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system.Considerations on long-term immuno-intervention in the treatment of multiple sclerosis: an expert opinion.A unique amidoanthraquinone derivative displays antiproliferative activity against human hormone-refractory metastatic prostate cancers through activation of LKB1-AMPK-mTOR signaling pathway.Can new chemical therapies improve the management of multiple sclerosis in children?Survival of de novo and secondary acute promyelocytic leukemia: a propensity-matched analysis of the SEER database.Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis.Long-term treatment risks in multiple sclerosis: risk knowledge and risk perception in a large cohort of mitoxantrone-treated patients.Current therapeutic options in pediatric multiple sclerosis.
P2860
Q28480940-404D755B-1E9C-4DF6-B237-B5710AD9CCA5Q34066839-8E3A490E-C07A-4E7F-82A0-FD2DB1ABFC66Q34351253-CBD20CFD-F89F-4303-8165-E6097DE3E928Q34750640-34A51396-B3EF-47F7-80D8-79592383A30BQ34810005-930EF63B-24A2-4560-B7AF-E2D16F460F70Q34922742-9BFE5694-D0A4-498C-A8B5-199EE1B39980Q35231673-BC393408-6830-47D0-A3DB-681A6813822FQ35825923-6E070590-BB43-4325-B206-EE5F17D2EA39Q36006358-AE69216A-D3E5-44D9-8A0F-8C073A79B141Q36627692-BECC5BA5-C1B9-40AD-B936-5C2082BBACA3Q36975701-B68DFBE6-8F9E-4383-B70D-F5DED7687213Q37562166-E5DFE812-1D53-4478-8445-6D1B688DE78AQ37576054-0222240F-9E8E-4055-AF94-3F978E9B92D0Q37693918-65A09A82-1394-4C3A-B48D-710B2B8BC603Q37827690-63C715DA-4001-40CE-82F9-32E33E284C3FQ37849763-AADFC659-5A68-4091-9E14-5EBC12B4C219Q37855722-B5A47246-74B9-46DA-97E0-7CB06CC9A907Q38002113-D75EBCAF-5C74-4F43-8854-1A5A02DEB00EQ38036853-4BA0D225-C018-4FA7-BE31-F82187272655Q38172961-CAE70C82-8134-4DD2-AAE3-61F1D0D63292Q38946338-37A94428-4BD6-41BB-BA8D-C4D307422CE1Q38977013-7F04675D-E0ED-4CBB-9844-B19CE9EA57F5Q39024427-EB61408D-7C2A-408E-9A8D-D3398DD600B9Q41662169-E109EF79-FA7E-4AE5-8D7A-C8899B96FE7FQ42920232-11121159-483D-467E-9F60-C6D197C59D75Q45354300-6C8C0B6D-1848-435E-89D5-82935866A65EQ48805758-67218F67-EAF4-4919-BA08-357F1AFDDB18
P2860
Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Revision of the risk of second ...... rosis populations is required.
@en
Revision of the risk of second ...... rosis populations is required.
@nl
type
label
Revision of the risk of second ...... rosis populations is required.
@en
Revision of the risk of second ...... rosis populations is required.
@nl
prefLabel
Revision of the risk of second ...... rosis populations is required.
@en
Revision of the risk of second ...... rosis populations is required.
@nl
P2093
P2860
P356
P1476
Revision of the risk of second ...... erosis populations is required
@en
P2093
Ana M Pascual
Angel P Sempere
Antonio Belenguer
Bonaventura Casanova
Francisco Coret
Inmaculada Abellán
Isabel Boscá
Javier Mallada
Ma José Magraner
Neus Téllez
P2860
P304
P356
10.1177/1352458509107015
P577
2009-10-13T00:00:00Z